What's driving the Cancer supportive care products Market Trends? Amgen, Johnson & Johnson, Novartis Ag, Baxter International, Fagron Group BV, Hoffmann LA- Roche Inc, Acacia Pharma Ltd

The strong prevalence of cancer and the chronicity of the disease is the primary driver of the global cancer supportive care products market. There will be nearly 24 million cancer patients across the world by 2035 according to a recent report by the WCRF and most of them will need care for quite a number of years as cancer does not cause sudden death in most cases. A number of healthcare organizations have recognized the escalating demand from cancer patients and are opening specialized care centers as well as investing in the research and development of products that serve them adequately.

Some of the other factors augmenting demand in the global cancer supportive care products market are: increasing geriatric population who are more prone to the disease, greater effectiveness of anti-cancer treatments, rising prevalence of several forms of cancer, high demand for improved cancer supportive care therapies, increasing focus on maintaining superior quality of life, and availability in alternative dosage forms in compounding pharmacies.

Request Sample of This Report @ https://www.persistencemarketresearch.com/samples/5336

On the other hand, loss of brand exclusivity of various generic drugs, entry of biosimilars, rising costs of innovation holding R&D investments, and regulatory barriers are some of the key factors restraining the cancer supportive care products market. Therefore, lack of blockbuster drugs would mean that in the next five years, the market would be defined in part by development of new formulas, combinations, and delivery devices.

Competitive Landscape
• Amgen Inc.
• Johnson & Johnson Private Ltd.
• Novartis AG
• Baxter International Inc
• Hoffmann-La Roche Ltd.
• Fagron Group BV
• Teva Pharmaceutical Industries Ltd.

As the PMR report foresees the future of the cancer supportive care products market, the demand will expand at a notable CAGR of 4.8% during the forecast period of 2017 to 2021. In terms of revenue, the concerned market is poised to attain a valuation of US$ 31,700.0 Mn by the end of 2021, considerably more than its evaluated 2017 worth of US$ 26,285.5 Mn in 2017.

On the basis of drug class, the report segments the market for cancer supportive care products into nonsteroidal erythropoietin stimulating agents, opioid analgesics, anti-imflammatory drugs, anti-infective drugs, bisphosphonates, anti-emetics drugs, monoclonal antibodies, and granulocyte colony stimulating factor. Indication-wise, the market has been bifurcated into lung cancer, prostate cancer, breast cancer, leukemia, ovarian cancer, bladder cancer, liver cancer, melanoma, and others.

Request For Methodology @ https://www.persistencemarketresearch.com/methodology/5336

On the other hand, loss of brand exclusivity of various generic drugs, entry of biosimilars, rising costs of innova-tion holding R&D investments, and regulatory barriers are some of the key factors restraining the cancer support-ive care products market. Therefore, lack of blockbuster drugs would mean that in the next five years, the market would be defined in part by development of new formulas, combinations, and delivery devices.

Table of Contents

1. Executive Summary
2. Research Methodology
3. Assumption & Acronyms Used
4. Market Overview
4.1. Parent Market Overview

4.2. Market Taxonomy & Market Definition
4.3. Global Cancer Supportive Care Products Market Size and Forecast
4.3.1. Introduction
4.3.2. Market Value Forecast & Y-o-Y Growth Rate (2015-2021)

4.4. Global Cancer Supportive Care Products Market Dynamics
4.4.1. Drivers
4.4.2. Restraints
4.4.3. Trends
4.4.4. Opportunity

5. Regulations & PEST Analysis
6. Global Cancer Supportive Care Products Market Analysis and Forecast By Drug Class
6.1.1. Introduction
6.1.2. Y-o-Y Growth Comparison, By Drug Class
6.1.3. BPS Analysis, By Drug Class

6.1.3.1. Nonsteroidal Anti-inflammatory Drugs
6.1.3.2. Anti-infective
6.1.3.3. Anti-emetics
6.1.3.4. Monoclonal Antibodies

6.1.3.5. Erythropoietin Stimulating Agents
6.1.3.6. Opioid Analgesics
6.1.3.7. Bisphosphonates
6.1.3.8. Granulocyte Colony Stimulating Factor
6.1.4. Global Cancer Supportive Care Products Market Attractiveness Analysis By Drug Class

Buy Now @ https://www.persistencemarketresearch.com/checkout/5336

ABOUT US:

Persistence Market Research (PMR) is a third-platform research firm. Our research model is a unique collaboration of data analytics and market research methodology to help businesses achieve optimal performance. To support companies in overcoming complex business challenges, we follow a multi-disciplinary approach. At PMR, we unite various data streams from multi-dimensional sources. By deploying real-time data collection, big data, and customer experience analytics, we deliver business intelligence for organizations of all sizes.

CONTACT:
Persistence Market Research
305 Broadway
7th Floor, New York City,
NY 10007, United States,
USA – Canada Toll Free: 800-961-0353
Email: sales@persistencemarketresearch.com
Web: http://www.persistencemarketresearch.com

This release was published on openPR.